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In recent years, peroxisome proliferator-activated receptor gamma (PPARγ) has been reported to be a target for the treatment
of type II diabetes. Furthermore, it has received attention for its therapeutic potential in many other human diseases, including
atherosclerosis, obesity, and cancers. Recent studies have provided evidence that the endogenously produced PPARγ antagonist,
2,3-cyclic phosphatidic acid (cPA), which is similar in structure to lysophosphatidic acid (LPA), inhibits cancer cell invasion and
metastasis in vitro and in vivo. We recently observed that cPA negatively regulates PPARγ function by stabilizing the binding of
the corepressor protein, silencing mediator of retinoic acid and thyroid hormone receptor. We also showed that cPA prevents
neointima formation, adipocyte diﬀerentiation, lipid accumulation, and upregulation of PPARγ target gene transcription. We
then analyzed the molecular mechanism of cPA’s action on PPARγ. In this paper, we summarize the current knowledge on the
mechanism of PPARγ-mediated transcriptional activity and transcriptional repression in response to novel lipid-derived ligands,
such as cPA.
1.Introduction
Nuclear receptors (NRs) bind to small lipophilic molecules,
such as steroids [1]t h y r o i dh o r m o n e sa n da c t i v ef o r m s
of retinoids [2]. Peroxisome proliferator-activated receptors
(PPARs) were originally cloned as orphan receptors in 1990
[1, 3]. There are 48 members encoded in the human genome
[4]. Subsequently, several clinical studies were performed
on cloﬁbrates as ligands for PPARα [5, 6]. PPARα is highly
expressed in the liver and is considered the key player
in the hepatic fasting response [7, 8]. Cloﬁbrates are a
pharmaceutical tool for reducing triglyceride levels and
increasing high-density lipoprotein (HDL) cholesterol [9].
Other closely related receptors encoded by diﬀerent genes
were subsequently cloned and named PPARδ [10]a n d
PPARγ [11].
PPARγ i sam e m b e ro ft h en u c l e a rr e c e p t o rg e n ef a m i l y
that plays a central role in the regulation of glucose and
lipidhomeostasis.ActivationofPPARγ bythiazolidinediones
(TZDs)leadstoalteredmetabolisminadiposetissue,skeletal
muscle cells, and liver, resulting in insulin sensitization
[12]. PPARγ agonists also promote adipocytic diﬀerentiation
of 3T3-L1 cells and stimulate the uptake of low-density
lipoprotein (LDL) by macrophages, leading to foam cell
formation in the arterial wall [13, 14]. There is considerable
evidence supporting a deleterious role for oxidized phos-
pholipids and fatty acids as important signaling molecules
in the context of atherosclerotic lesions [15]. Rother et al.
reportedthatlysophosphatidicacid(LPA)Gprotein-coupled
receptor (GPCR) antagonists abolish platelet aggregation
elicited by mild oxidation of LDL (mox-LDL), indicating
that LPA plays an essential role in the thrombogenic eﬀects
of mox-LDL [16]. When applied topically to the carotid
artery wall in rodents, LPA and the TZD drug rosiglitazone
induced PPARγ-mediated intimal thickening [13]. Although
their functional roles in the PPARγ transcriptional pathway
are not well deﬁned, we recently found that production
of cyclic phosphatidic acid (cPA), a simple phospholipid,
inhibits transcription of PPARγ target genes that nor-
mally drive adipocytic diﬀerentiation, lipid accumulation in
macrophages, and arterial wall remodeling [14]. We also
investigated the structure-activity relationship of activation
by naturally occurring lysophospholipids. We found that2 PPAR Research
cPA inhibits PPARγ [14, 17] with high speciﬁcity through
stabilizing its interaction with the corepressor, silencing
mediator of retinoic acid and thyroid hormone receptor
(SMRT) [14]. These results suggest that cPA is partly
mediated by the PPARγ signaling pathway. In this paper,
we focus on recent advances in the understanding of the
interaction of PPARγ with lipid-derived ligands, particularly
focusing on the regulation of PPARγ in response to the
endogenous lysophosphatidic acid analogs LPA, alkyl-LPA,
and cPA.
2.Mechanismof PPARγ-MediatedEffects
2.1. Agonist Regulation of PPARγ. PPARγ is most often
implicated in lipid metabolism and insulin sensitivity [18,
19]. There are 2 PPARγ isoforms, PPARγ1 and PPARγ2.
PPARγ2 has 30 additional amino acids at the N-terminus in
humans [20] and is generated from the same gene by mRNA
splicing [21]. While PPARγ1 is expressed with a broad tissue
distribution, PPARγ2 is highly expressed in adipocytes [22],
adipose tissue [19], macrophages [23], stomach [24, 25], and
colon [26–28]. The role of PPARγ has been extensively stud-
ied,andavarietyofsyntheticandphysiologicalagonistshave
been identiﬁed. Several lines of study have suggested that the
binding of diﬀerent PPARγ ligands can induce a range of
distinct PPARγ conformations [29]. PPARγ contains a DNA-
binding domain (DBD) that binds to hormone response
elements in the promoter of its target genes. Upon agonist
binding, PPARγ forms a heterodimer with retinoid X recep-
tors (RXRs). PPARγ activation induces a conformational
change in the ligand-dependent activation domain (AF-
2 helix) located in the c-terminal ligand-binding domain
(LBD), which allows coactivator recruitment, corepressor
release, and formation of the heterodimeric PPARγ-RXR
complex. PPARγ-RXR heterodimer binds the peroxisome
proliferatorresponseelement(PPRE)inthepromoterregion
of the target genes [30, 31]. The PPARγ-LBD is composed
of 13 α-helices and a small 4-stranded β-sheet that forms a
∼1440-˚ A hydrophobic ligand-binding pocket of the nuclear
receptor, which binds many diﬀerent ligands [32]. Together,
these ﬁndings suggest that these domains are involved
not only in ligand recognition but also in protein-protein
interactions.
2.2. Synthetic and Natural PPARγ Agonists. In the last
decade,bothsyntheticandnaturalPPARγ agonistshavebeen
explored for their biological and physiological functions
[33]. Synthetic PPARγ agonists, which include rosiglitazone
(Avandia) (Figure 1)[ 34, 35], troglitazone (Rezulin, with-
drawn by the FDA due to causing liver failure) [36, 37],
and pioglitazone (Actos; Takeda Pharmaceutical Ltd.) [38,
39], have provided insight into the therapeutic potential of
PPARγ. These compounds are speciﬁc PPARγ ligands with
Kds in the 40–500nM range [34, 40]. They are eﬀective
as insulin-sensitizing agents, reducing insulin resistance
and lowering plasma glucose levels in patients with type
II diabetes (previously known as noninsulin-dependent
diabetes mellitus, NIDDM). Recently, these drugs have also
been found to be eﬀective in regulating cell proliferation
and diﬀerentiation [25]. PPARγ activation by its ligands
can induce growth arrest, diﬀerentiation, and apoptosis of
cancer cells. Similarly, PPARγ heterozygous knockout mice
have increased susceptibility to chemical carcinogens [41].
Nevertheless, these reports remain controversial and are not
well supported. For instance, low concentrations of PPARγ
ligands increase cell proliferation, while high concentrations
inhibit cell growth in MDA-MB-231 breast cancer cells [42].
The eﬀective clinical dose of rosiglitazone used in diabetes
is 0.11mg/kg/day [43]. In contrast, the antitumor activity
of rosiglitazone in mice requires 100–150mg/kg/day [43],
which is 1,000-fold higher. Therefore, the dosage of PPARγ
agonists for cancer therapy must be carefully deﬁned in
clinical trials. A recent report suggested that physiological
agonists included polyunsaturated acids, such as eicosapen-
taenoic acid (EPA) [44], linoleic acid [45], and oxidized
fatty acid metabolites, cyclopentenone prostaglandin 15-
deoxy-Δ12,14 (15d-PGJ2)[ 46], 8(S)-hydroxyeicosatetraenoic
acid (8(S)-HETE) [47], and the lipoxygenase product, 9-
hydroxyoctadecadienoic acid (HODE) [23]. These results
were surprising, because these compounds are known to
mediate their biological eﬀects through interacting with
cell-surface GPCRs, including prostaglandin D2 receptors
(DP)1−2 and G protein-coupled receptor 44 (GPR44),
prostaglandin E receptors (EP)1−4, prostaglandin F recep-
tor (FP), prostacyclin receptors (IP)1−2, and thromboxane
receptors (TP). However, in 1995, Forman et al. ﬁrst
reported that the prostaglandin J2 derivative, 15d-PGJ2,w a s
a natural intracellular agonist of PPARγ as well as a factor
of adipocyte determination [46]. 15d-PGJ2 is a product
of the cyclooxygenase pathway and is the ﬁnal metabolite
of prostaglandin D2 (PGD2). Some J-series prostaglandins
have been found to bind to PPARγ in the low micromolar
range [48]. Although 15d-PGJ2 was initially identiﬁed as a
high-aﬃnity endogenous ligand (Kd = 300nM) [46], the
physiologicalroleof15d-PGJ2 remainsunclear.Inparticular,
its concentration in vivo is much lower than that required for
itsbiologicalfunctions[49].Furthermore,apoptosisinduced
by 15-PGJ2 occurs independently of PPARγ activation and
may result from a loss of mitochondrial membrane potential
and the formation of reactive oxygen species (ROS) [50, 51].
2.3. Lipid-Derived PPARγ Agonists. A number of natural
ligands for PPARγ have been identiﬁed and include 2
main groups of compounds, fatty acids, and phospholipids.
More recently, select phospholipids, such as LPA [52],
alkyl-glycerophosphate (alkyl-LPA) [53], hexadecyl azelaoyl
phosphatidylcholine (azPC) [54], and nitrolinoleic acid and
relatedmetabolites [55],havebeenidentiﬁed. LPA (Figure 1)
has been reported as a bioactive lipid and is derived from
hydrolysis of plasma membrane phospholipids [56, 57].
LPA is already wellestablished as a ligand for speciﬁc LPA
GPCRs belonging to the endothelial cell diﬀerentiation gene
family [58] and is formed during mox-LDL [13]. Although
exogenous LPA can activate PPARγ [52, 59], the reported Kd
of PPARγ with acyl-LPA(18:1) is in the high micromolar
range, which is at least an order of magnitude higherPPAR Research 3
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Figure 1: Structural formulas of LPA, alkyl-LPA, cPA,and rosiglita-
zone. LPA is made up of a glycerol backbone with a hydroxyl group,
a phosphate group, and a long-chain saturated or unsaturated fatty
acid. Alkyl-LPA is an alkyl-ether analog of LPA. Alkyl-LPA shows a
higher potency than LPA at the intracellular LPA receptor PPARγ.
cPA is a naturally occurring acyl analog of LPA. cPA is a weak
agonist of plasma membrane LPA receptors, whereas cPA is an
inhibitorofPPARγ.Rosiglitazoneisathiazolidinedione(TZD)class
of antidiabetics and is full agonist of PPARγ.
than its physiological concentration [52]. Examining the
speciﬁcity of lipid-derived ligands, such as LPA, for PPARγ
is complicated by their poor water solubility and by the need
to physically separate PPARγ-bound and -free ligands for
measuringtheKd.Poorwatersolubilityleadstoahighdegree
ofnonspeciﬁcbinding andreducesphysiologicalsigniﬁcance
[60]. However, Davies et al. ﬁrst reported an oxidatively
fragmented alkyl phospholipid in oxidized LDL (oxLDL),
termed azPC, as a high-aﬃnity phospholipid-derived ligand
ofPPARγ [54].RadiolabeledazPCwasshowntobindPPARγ
with an aﬃnity of approximately 40nM, which is equivalent
to TZD drugs, like rosiglitazone [54]. Shortly after, our
group identiﬁed a naturally occurring ether analog of LPA,
alkyl-LPA (Figure 1), a high-aﬃnity partial agonist of PPARγ
[53]. Alkyl-LPA, but not acyl-LPA, accumulates in mox-LDL
and more potently activates PPARγ-mediated transcription
compared to acyl-LPA [53]. Binding studies using γ-globulin
and polyethylene glycol 8000 (PEG) precipitation showed
that binding of radiolabeled alky-LPA was concentration
dependent and saturable with an apparent Kd of 60nM
[53]. To determine the molecular basis of the high-aﬃnity
binding to PPARγ, we used molecular modeling techniques
to computationally dock alkyl-LPA within the PPARγ pocket
residues [53]. Ligand-binding speciﬁcity was imposed by
the size and charge of the amino acids lining the ligand-
binding pocket [61]. Alkyl-LPA hydrocarbons did not form
hydrogen bonds with the 2 histidines (His-323 and His-
449) as rosiglitazone does [53]. In contrast, the phosphate
head group of alkyl-LPA is predicted to make a salt bridge
with Arg-288, a residue that is not engaged by rosiglitazone
[53]. R288A mutants showed reduced alkyl-LPA binding
and reduced transcriptional activity in response to 10μM
alkyl-LPA [53]. The Arg-288 residue likely plays a role in
distinguishing the interactions of PPARγ with alky-LPA
versus rosiglitazone [53]. These results highlight distinct
interactions between alkyl-LPA and rosiglitazone with select
residues within the PPARγ-ligand-binding domain.
3.SyntheticandNaturalPPARγ Antagonists
Asmentionedabove,manystudieshaveinvestigatedtheroles
of PPARγ agonists in many diseases, such as cardiovascular
disease in diabetics [62], autoimmune encephalomyelitis
[63], lung disease [64], and Alzheimer’s disease [65]. How-
ever, relatively few reports have described the mechanisms
of PPARγ antagonists. Wright et al. reported that bisphenol
A diglycidyl ether (BADGE), which is a compound used
in the manufacture of industrial plastics, is a synthetic
antagonist of PPARγ with a Kd of 100μM[ 66]. BADGE
can antagonize rosiglitazone’s activation of PPARγ tran-
scriptional activity and adipogenic action in 3T3-L1 and
3T3-F442A preadipocyte cells. BADGE also aﬀected the
expression of diﬀerent adipocyte-speciﬁc markers, includ-
ing adipocyte fatty acid-binding protein (aP2), glycerol-3-
phosphate dehydrogenase (GPD), glucose transporter type
4 (GLUT4), and adipsin. However, Bishop-Bailey et al.
reportedthatBADGEisaPPARγ agonistin ahumanurinary
bladder carcinoma cell line, ECV304, that stably expresses
the rat acyl-CoA PPAR response element (PPRE) linked
to drive the expression of luciferase [67]. Furthermore,
Nakamura et al. reported that BADGE is a PPARγ agonist
in the macrophage-like cell line, RAW 264.7, and suppressed
tumornecrosisfactor-alpha(TNF-α)pr oduction[68].These
reports suggest that the regulation of PPARγ activation
or inhibition may have greater cell-type speciﬁcity than
previously thought. Rieusset et al. reported that dimethyl
α-(dimethoxyphosphinyl)-p-chlorobenzyl phosphate (SR-
202) is a selective synthetic PPARγ antagonist that blocks
adipocyte diﬀerentiation induced by troglitazone [69]. SR-
202 attenuates agonist-induced PPARγ transcriptional activ-
ity (IC50 = 140μM) and improves insulin sensitivity in
diabetic ob/ob mice. It also increases HDL levels in rats,
indicating its potential for treating obesity and type II
diabetes. PD068235, a reported PPARγ antagonist, inhibited
rosiglitazone-dependent PPARγ transcriptional activity with
an IC50 of 0.84μM and prevented association with the
agonist-induced coactivator, SRC-1 [70]. PD068235 itself
did not signiﬁcantly change PPARγ transcriptional activity;4 PPAR Research
however, cotreatment with rosiglitazone dose dependently
decreased PPARγ transcriptional activity.
2-chloro-5-nitrobenzanilide (GW9662) is a potent, irre-
versible, and selective PPARγ antagonist (IC50 = 3.3nM) in
both cell-free and cell-based assays, which acts by covalently
modifying a cysteine residue (Cys 286) in the PPARγ-LBD
[71]. Interestingly, GW9662 enhanced the inhibitory eﬀect
of the agonist rosiglitazone on breast cancer cells rather than
rescuing tumor growth, suggesting that PPARγ activation
may not be involved in inhibition of survival and cell growth
caused by agonists [72]. In 2002, a very potent and selective
non-TZD-derived PPARγ antagonist, 2-chloro-5-nitro-N-4-
pyridinylbenza (T0070907), was newly identiﬁed [73]. It was
reported to bind PPARγ with a high aﬃnity (IC50 = 1nM)
and block adipocyte diﬀerentiation. Furthermore, T0070907
promoted the recruitment of the transcriptional corepressor
NCoR [74] as a result of binding to PPARγ and causing
conformational changes. In contrast, very few endogenous
PPARγ antagonists have been described. Prostaglandin F2α
(PGF2α) was ﬁrst described as naturally occurring PPARγ
antagonist; it potently inhibits adipocyte diﬀerentiation in
3T3-L1 cells [75]. A main step in the synthesis of PGF2α
is the conversion of arachidonic acid into the unstable
intermediate prostaglandin H2 (PGH2) through the activity
of cyclooxygenase (COX) [76]. PGF2α induces MAP kinase
activation, leading to the phosphorylation of PPARγ at Ser
112. This eﬀect suggests that PGF2α indirectly antagonized
PPARγ induction and inhibited adipocyte diﬀerentiation
[75]. Our recent work identiﬁed cPA (Figure 1)a san a t u ra ll y
occurring PPARγ antagonist generated by phospholipase
D2 (PLD2). cPA is an analog of LPA with a 5-atom ring
linking the phosphate to 2 of the glycerol carbons. cPA is
found in diverse organisms, from slime mold to humans
[77, 78]; however, its functions are largely unknown. The
concentration of cPA in human serum is estimated to be
∼10nM, which is ∼100-fold lower than that of LPA.
Although cPA is structurally similar to LPA, it has several
unique actions. cPA inhibits cell proliferation, induces actin
stress ﬁber formation, promotes diﬀerentiation and survival
of cultured embryonic hippocampal neurons, inhibits LPA-
induced platelet aggregation, and suppresses cancer cell
invasion and metastasis in vitro and in vivo [79–81].
4. TranscriptionalCorepressorsand
EpigeneticModiﬁcations
4.1. PPARγ Ligands and Epigenetic Control. We showed that
cPA negatively regulates PPARγ functions by stabilizing the
SMRT-PPARγ complex [14]. Epigenetic mechanisms are
often responsible for regulating speciﬁc gene activation and
repression [82]. DNA methylation and histone modiﬁcation
serve as epigenetic markers for active or inactive chromatin.
Gene repression through posttranslational modiﬁcation is
targeted to speciﬁc DNA sites through DNA methylation
[83]. Epigenesis plays a vital role in the regulation of gene
expression; DNA methylation plays an important role in
these structural changes [84]. DNA methylation occurs on
cytosine bases and is catalyzed by DNA methyltransferases.
In general, DNA methylation is thought to repress gene
transcription through either directly preventing the binding
of transcription factors or by creating binding sites for
methyl-binding proteins [85]. Several studies have reported
that epigenetic regulatory mechanisms are involved in the
transcriptional activation of PPARγ in 3T3-L1 adipocytes
[86]. Fujiki et al. recently reported that the PPARγ gene is
regulated by DNA methylation of its promoter region, which
reduces expression of PPARγ [87]. These ﬁndings suggest
that DNA methylation of the PPARγ promoter contributes
to its expression during adipocyte diﬀerentiation.
Acetylation of core histone proteins occurs on speciﬁc
lysine residues, creating a neutral charge that loosens DNA-
histoneinteractionsandpermitsthebinding oftranscription
factors [88]. Many proteins have been identiﬁed as coreg-
ulators that can be recruited by nuclear receptors to aﬀect
transcriptional regulation. The corepressor for PPARγ is a
protein complex containing histone deacetylase 3 (HDAC3)
a n dS M R To rN C o R .An u m b e ro fP P A R γ interacting
partners have been identiﬁed, many of which are known
epigenetic regulators, including HDAC3 [89, 90]. HDACs
repress gene expression by deacetylating histones and
condensing chromatin. Many nuclear receptors, including
PPARγ in the unligated or antagonist-bound state, repress
transcription by recruiting corepressors [91, 92], which bind
to the heterodimer to suppress target gene activation. The
n u c l e a rr e c e p t o rc o r e p r e s s o rN C o Ra n dS M R Ta r es t r u c -
turally related and extensively studied corepressors. NCoR
and SMRT are encoded by separate loci but share a similar
modular structure. The N-terminus contains several repres-
sion domains (RDs). The PPARγ AF2 domain is accessible
and can interact with the extended LXXXIXXXL consensus
motif of NR corepressors [93]. These corepressor complexes
signiﬁcantly regulate the control of transcription in inactive
states [8]. NCoR and SMRT nucleate a core corepressor
complex that contains HDAC3, transducin β-like 1 (TBL1),
TBL1-related protein (TBLR1), and G protein pathway sup-
pressor 2 (GPS2), forming a functional holocomplex [94].
HDAC3 is found in a tight complex with SMRT and NCoR
in diverse repression pathways [95]. These 2 corepressors
recruit HDAC3 to speciﬁc promoters, where it deacetylates
histones and mediates silencing of the corresponding genes.
TBL1 is a 6 WD-40 repeat-containing protein (also known as
beta-transducinrepeat)thatwasidentiﬁedasasubunitofthe
SMRT complex [96]. Both TBL1 and TBLR1 interact directly
with SMRT and NCoR but not with HDAC3. They activate
PPARγ-dependenttranscriptioninresponsetorosiglitazone.
The transcriptional activity of PPARγ is controlled by DNA-
binding activity and nuclear receptor cofactors [97]. These
corepressor complexes associate with a variety of factors that
mediate transcription repression.
4.2. cPA-Induced Corepressor SMRT and Interaction with
Human Diseases. Our recent report used a corepressor 2-
hybrid assay to show that cPA negatively regulates PPARγ
function by stabilizing the SMRT-PPARγ complex (Figure 2)
and blocks rosiglitazone-stimulated adipogenesis and lipidPPAR Research 5
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Figure 2:SchematicdiagramofthePPARγ signaling.cPAisgeneratedintracellularlyinastimulus-coupledmannerbythePLD2enzyme(1).
cPA inhibits PPARγ activation and stabilizes binding of PPARγ corepressor SMRT (2). Agonists (LPA, alkyl-LPA, and rosiglitazone) activate
PPARγ and promote downstream signals, whereas cPA negatively regulates PPARγ. cPA stabilizes PPARγ-SMRT corepressor complex and
inhibits PPARγ-mediated postsignal transduction (3).
accumulation in 3T3-L1 and RAW246.7 macrophage-like
cells [14]. This ligand-dependent corepressor exchange
results in transcriptional repression of genes involved in
the control of insulin action as well as a diverse range of
other functions [98]. We also demonstrated that activation
of PLD2-mediated cPA production by insulin or topical
application of cPA together with PPARγ agonists prevents
neointima formation, adipocytic diﬀerentiation, lipid accu-
mulation, and upregulation of PPARγ target genes [13,
14]. Atherosclerosis is the leading cause of death among
cardiovascular diseases. Neointima formation is a common
feature of an atherosclerotic artery and is characterized by
smooth muscle cell (SMC) proliferation and extracellular
matrix deposition in the vascular intimal layer. Yoshida et al.
ﬁrst reported that LPA and species containing unsaturated
LPA (16:1, 18:1 and 18:2) induced neointima formation
when injected into the rat carotid artery [99]. Furthermore,
LPA and alkyl-LPA induced neointima formation through
the activation of PPARγ, whereas cPA inhibited PPARγ-
mediated arterial wall remodeling in a noninjury infusion
model [13, 14]. These results suggest that PPARγ is required
for LPA-induced neointima formation. PPARγ antagonists
should continue to be developed, as they have the clinical
potential for preventing neointimal vascular lesions.
5. Conclusion
In this paper, we have focused on recent developments
elucidating the role of lysophospholipids in intracellular sig-
naling and PPARγ activation and inhibition. Our proposed
mechanism of action for the cPA-PPARγ axis is summarized
in Figure 2. Lysophospholipids fulﬁll dual role as mediators,
through the activation of cell surface GPCRs, and as
intracellular second messengers, through the activation and
inhibition of PPARγ.P P A R γ-corepressor interactions are
physiologically relevant, as reports have demonstrated the
involvement of chromatin-modifying cofactors in diseases,
such as cancer [100] and metabolic syndrome diseases [101].
However, the physiological context of these compounds in
PPARγ signaling is still unclear. Further clariﬁcation of the
PPARγ-cPA axis could allow the synthesis of novel medicines
that modulate PPARγ.
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